POPULARITY
27 episodes with Jaks
7 episodes with Jaks
3 episodes with Jaks
2 episodes with Jaks
2 episodes with Jaks
4 episodes with Jaks
2 episodes with Jaks
2 episodes with Jaks
2 episodes with Jaks
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1
Bathing frequency doesn't matter in AD -Tapering down JAKs in AD -Oral plasma cell mucositis -IL sodium thiosulfate for calcinosis cutis - Check out Luke's Urticaria CME experience! aaaaicsu.gathered.com/invite/KQe1wPZbJY Learn more about the U of U Dermatology ECHO model! physicians.utah.edu/echo/dermatology-primarycare Want to donate to the cause? Do so here! Donate to the podcast: uofuhealth.org/dermasphere Check out our video content on YouTube: www.youtube.com/@dermaspherepodcast and VuMedi!: www.vumedi.com/channel/dermasphere/ The University of Utah's Dermatology ECHO: physicians.utah.edu/echo/dermatology-primarycare - Connect with us! - Web: dermaspherepodcast.com/ - Twitter: @DermaspherePC - Instagram: dermaspherepodcast - Facebook: www.facebook.com/DermaspherePodcast/ - Check out Luke and Michelle's other podcast, SkinCast! healthcare.utah.edu/dermatology/skincast/ Luke and Michelle report no significant conflicts of interest… BUT check out our friends at: - Kikoxp.com (a social platform for doctors to share knowledge) - www.levelex.com/games/top-derm (A free dermatology game to learn more dermatology!
Not all JAKs are the same: Learn how JAKs can help your patients. Credit available for this activity expires: 12/05/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/exploring-jak-inhibitors-atopic-dermatitis-2025a1000xqp?ecd=bdc_podcast_libsyn_mscpedu
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES 1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron's, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV 2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9 3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs 4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm 5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj 6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww 7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). 8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y 9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025 10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000 https://t.co/o7BaWjS4HB
This episode explores the grit, growth, and grace behind building a successful ranch from the ground up. Luke and Natalie share how they turned a shared dream into a working legacy—growing from a small commercial herd to a nationally recognized registered Angus operation known for elite genetics and a customer-first mindset.We dive into:The early years—from purchasing their first commercial cows to flushing embryos and selling top-tier bulls.The business evolution—including their first online bull sale in 2021 and the move to their first live auction in 2024, which featured the $150,000 high-selling LT Talent bull.Faith and family balance—how they juggle running a ranch, raising three kids (Tad, Jaks, and Rue), and staying grounded in what matters most.Natalie's journey from pharmacy to ag advocacy, building an online platform that reaches over 200,000 followers across Instagram, TikTok, and podcasting.Luke's focus on genetics, performance, and sustainability, emphasizing that profitability and maternal strength go hand-in-hand.Their vision for the future, from expanding their herd to mentoring the next generation of producers and continuing to grow the ranch's reputation for quality and integrity.Listeners will also get a behind-the-scenes look at how Kovarik Cattle Co uses AI, embryo transfer, and genomic testing to stay on the cutting edge, while keeping family and faith at the heart of every decision.
DERM on RheumNow PODCAST (October 2025) Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES 1. Skin Biopsies to Predict Scleroderma Outcomes? 2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8 3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis 4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH 5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz 6. Mediterranean Diet Efficacy in Psoriasis 7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes
Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs wont do & an FDA Pink Slip.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Andy Blauvelt, MD, to explore the mechanism, efficacy, and safety of deucravacitinib, the first FDA-approved tyrosine kinase 2 (TYK2) inhibitor for psoriasis. Dr Blauvelt begins by explaining how TYK2 inhibition differs from traditional JAK inhibition by targeting a more selective signaling pathway downstream of cytokine receptors. Unlike JAK1, JAK2, or JAK3, TYK2 is involved in a narrower range of cytokines, which may explain its distinct safety profile. Dr Del Rosso and Dr Blauvelt also clarify why deucravacitinib lacks the boxed warning seen with other oral JAK inhibitors. With allosteric binding at the TYK2 pseudokinase domain, deucravacitinib avoids cross-inhibition of other JAKs, making it more selective and potentially safer. Long-term data now supports this distinction: 5-year safety results show no increased risk of major adverse cardiac events, malignancy, or serious infections, with only a small, manageable signal for herpesvirus infections. The conversation turns to efficacy, which appears sustained over 5 years without antibody development, a potential advantage over biologics. Dr Blauvelt emphasizes its utility in high-impact areas such as the scalp, palms, soles, genitalia, and nails, and encourages systemic therapy even in patients with limited body surface area involvement when quality of life is severely affected. Tune in to the full episode to learn how deucravacitinib fits into the current psoriasis treatment algorithm, what sets TYK2 inhibition apart from other oral options, and how real-world data is shaping clinical confidence in this novel therapy.
In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Diego Ruiz DaSilva, MD, dermatologist at Forefront Dermatology and assistant professor at Eastern Virginia Medical School. Together, they discuss Dr DaSilva's recent publications and his journey in building a collaborative research career focused on real-world clinical insights. To begin, Dr DaSilva shares the inspiration behind his recent publication that evaluated oral JAK inhibitors in elderly patients with moderate to severe atopic dermatitis. Motivated by the positive feedback from older patients and the perception that JAKs are underutilized due to safety concerns, he conducted a multicenter retrospective study that found strong efficacy and a reassuring safety profile in patients aged 65 to 96. Next, the discussion turns to nemolizumab, an IL-31 receptor antagonist recently approved for prurigo nodularis and atopic dermatitis. Dr DaSilva highlights a patient case that prompted a broader series: a patient with cancer experiencing recalcitrant itch who saw complete resolution within days of starting nemolizumab. Across 10 cases, 8 showed a rapid and marked itch response, with no adverse events or ocular surface issues. Finally, they review a case report on palmoplantar psoriasis treated with topical roflumilast 0.3% cream. Used initially as a bridge to systemic therapy, the patient achieved unexpectedly robust results with the topical alone, avoiding the need for a biologic. Dr DaSilva notes the importance of keeping nonsteroidal topicals in mind, especially for steroid-sparing strategies. Tune in to the full episode for more real-world data and case-based insights to help manage complex dermatologic conditions.
Mit Johannes Blumenberg als Gast sprechen wir über die Spiele SEVEN MERRY MONSTERS, KATHMANDU und INFERNO. Außerdem ist Johannes kürzlich veröffentlichte Studie "Board Game Content Creator Study" Thema in unserem Bargeflüster.
In this deeply challenging and thought-provoking episode of Dialogue over Division, we sit down with Maret Jaks to confront the harrowing issue of gang rapes in the UK. Together, we delve into the systemic failures of elected officials and police that have allowed these crimes to persist, examining the complex interplay of multiculturalism, political accountability, and justice. Maret draws on her extensive background in advocating for women's rights and identifying systemic weaknesses to provide incisive analysis and a passion for critical thinking in this vital conversation. She offers valuable insights into protecting vulnerable individuals while fostering meaningful dialogue about difficult and often uncomfortable topics. We explore the challenges of addressing multiculturalism with respect and nuance. While cultural diversity enriches our societies, it also requires careful balance to ensure the rights and safety of all citizens are upheld. Together, we discuss ways to hold systems accountable without vilifying communities, focusing instead on solutions that prioritize justice, equality, and transparency. The conversation expands beyond the UK, reflecting on the implications these issues have for Canada and other nations. We examine the media's role in covering—or sometimes neglecting—these crises, the failures of authorities to act, and the justice system's troubling inconsistencies. Additionally, we discuss how Canada can preserve its values of equality and respect within a multicultural framework. This episode is also a reminder of how extraordinary life in the West can be. Canada, and the West more broadly, offers some of the best places to live because of their foundation on the ideals of equal rights and opportunities for all. We, as citizens of these societies, have a responsibility to uphold these ideals, ensure they are not eroded, and foster a culture where they are respected and reciprocated by all. Above all else, it is imperative that we retain the courage and freedom to call attention to crimes and systemic issues, resisting any pressure to remain silent, or we risk losing everything. Let's work together to keep it that way. To do so, we must have open and honest conversations, free of shame or fear, and seek to build a brighter future by drawing on all of our cultural strengths. Only by speaking openly and fairly can we find common ground and strengthen our shared commitment to justice and inclusion. To dive deeper into Maret's insights and the foundation of her concerns, explore her book, Notes from a Blonde: Why This "Anything Goes!" Multiculturalism Has to Go (https://www.amazon.ca/Notes-Blonde-This-Anything-Multiculturalism/dp/1988470072). You can also follow her Substack newsletter, Not Your Donkey, for more thought-provoking discussions: https://maretjaks.substack.com/ Connect with Eva Chipiuk: Website: www.chipiuk.ca X/Rumble/YouTube: @echipiuk
A New ACR Cancer Survival in RA "Changing Mindsets about Methotrexate Side Effects" Control RA, Build Stronger Bones Cumulative Steroid Use and Cardiovascular Events Disease Activity in RA-ILD Do TNFis and JAKis Prevent Cancer!? Estimating Inflammation, Damage and Patient Distress Finding the Right Combination Therapy in RA Implantable Vagus Nerve Stimulator for RA Is Frequent Lab Monitoring Necessary? Long Term Follow up from APIPPRA Metabolic Dysregulation and RA Interstitial Lung Disease Native Americans with RA Die Young Paraoxonase-1: Possible Biomarker for Progression to RA Pred Softly: Steroids Predicting Flares in Rheumatoid Arthritis RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA Treatment Adherence: Is decision making really shared? RA: One JAK to Rule Them All? Sonelokimab in PsA: Phase 2 Data Treat-to-Target Improves Fertility in Women with RA Treatment Considerations for RA-ILD Treatment Strategies in RA Use of AI in Hand Ultrasound Scoring Vaccine Responses:The DMARD Counts What's New in Relapsing Polychondritis? What's The State of Biosimilars?
A New ACR Best Things I Saw Today in PsA Do TNFis and JAKis Prevent Cancer!? Hold or continue JAKi and IL-17 when receiving COVID boosters? JAK-pot! How fast do DMARDs work? JAKi Studies at ACR Poly-treatment of Polymyalgia Rheumatica? RA Roundup: Is LDA Inappropriate? What about Statins for JAKs? RA: One JAK to Rule Them All? SELECT-GCA: Efficacy and Safety of Upadacitinib "SELECT-GCA: Upadacitinib in Giant Cell Arteritis" SELECTing the right patients: upadacitinib in GCA So really, are JAKs Safe? Summary of JAKi Studies The Case for JAKi in PMR The Real Value of JAKi is Beyond RA When, What and How Long to Treat GCA & PMR Worried about CV Risk and JAKi? What about the Steroids?
Control RA, Build Stronger Bones:Dr. Jiha Lee talks with Dr. Rachel Elam Hold or continue JAKi and IL-17 when receiving COVID boosters?:Dr. Bella Mehta Long-term Safety Profile of Bimekizumab in axSpA and PsA:Dr. Philip Mease Navigating Rheumatology Care in Humanitarian Crisis Settings:Dr. Antoni Chan talks with Dr. Martha Dhzhus RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?:Dr. Eric Dein Sex Differences in Psoriatic Arthritis:Dr. Catherine Bakewell Single v Double Lung Transplants for Disease-related ILD:Dr. Eric Dein talks with Dr. Harry Hurley Sonelokimab in PsA: Phase 2 Data:Dr. Philip Mease Treating SpA:Dr. Marina Magrey
How do prescribers and patients determine whether or not a treatment for psoriasis or eczema provides meaningful response? And what is the right way to make a therapeutic switch? Wendy Cantrell, DNP, CRNP; Joe Gorelick, MSN, FNP-C; David E. Cohen, MD, MPH; and Kara Gooding, MMS, PA-C discuss. Plus, Steve Hawkes, MMS, PA-C shares tips on isotretinoin and Suneel Chilukuri, MD, talks exosomes science.Like what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.
Betti Alveri luuletekstidele loodud laule esitavad koos temaga Kostja Tsõbulevski, Sten Šeripov ja Kallervo Karu.
In this episode of Derms and Conditions, host James Del Rosso, DO, is joined by Jason Hawkes, MD, a dermatologist and investigator at the Medical Research Center of Oregon, to discuss tyrosine kinase 2 (TYK2) inhibitors, particularly deucravacitinib, for plaque psoriasis. They explain how deucravacitinib, which targets the TYK2 pathway, differs from other JAK inhibitors by avoiding the "off-target" effects associated with JAK 1, 2, and 3 inhibitors, offering a more selective and safe treatment option. They begin by discussing the JAK-STAT pathway, with Dr Hawkes noting that while the science behind it was well known, TYK2's role in psoriasis took time to fully understand. TYK2 regulates key cytokines like IL-12, IL-23, and type 1 interferons, which are critical in psoriasis and psoriatic arthritis. Its more focused role within the immune response reduces the risk of systemic side effects compared to broader-acting JAK inhibitors. They also explore deucravacitinib's selectivity, which targets the pseudokinase domain of TYK2, offering greater precision compared to inhibitors that target the ATP-binding domain shared by other JAKs. This selectivity results in deucravacitinib's cleaner safety profile, reflected in the lack of a boxed warning and minimal monitoring requirements. Finally, they review long-term data, noting deucravacitinib's superior efficacy to apremilast and a stable safety profile over four years. While some safety signals, like herpetic infections, slightly increased over time, most adverse events were stable or decreased. They conclude by discussing the importance of personalized treatment decisions, emphasizing deucravacitinib's advantages for patients who prefer oral medications and want to avoid injections. Tune in to the full episode for a comprehensive discussion on the clinical relevance of TYK2 inhibitors and the role of deucravacitinib in the psoriasis treatment landscape.
Ben Zimmer, CEO of Priovant Therapeutics, focuses on developing therapies for rare autoimmune diseases specifically dermatomyositis, which affects the skin, muscles, and organs, and non-infectious uveitis, a severe ocular inflammatory condition. While these conditions are symptomatically different, mechanistically, they have features in common related to the underlying pathology of the diseases. The drug in development is an oral once-daily therapy that addresses the inflammatory conditions and cytokines driving the pathology. Ben explains, "During COVID, there was a lot of talk about the cytokine storm and these are molecules involved in immune cell signaling. So, they're basically ways that different types of immune cells signal to each other to do different things. There's a large variety of different cytokines and some autoimmune diseases. There are only maybe one or two cytokines or a small number that are driving the pathology of the disease." "Both dermatomyositis and non-infectious uveitis are highly inflammatory conditions with a lot of different pathogenic cytokines, a lot of different inflammatory axes involved. And so, one of the neat things about our drug, brepocitinib, is that it works on a set category of enzymes called JAKs, and then there are four different types of JAKs, JAK1, JAK2, JAK3, and you might guess JAK4, but it's actually called TYK2. And our drug inhibits TYK2 and JAK1. And by doing that, it suppresses the signaling of a large number of different cytokines." "Uveitis and dermatomyositis have a number of overlapping pathogenic cytokines involved, as well as some different cytokines, but they are both suppressed through the inhibition of TYK2 and JAK1, which our drug does. So, our thesis is to find these highly inflammatory indications, highly inflammatory diseases with high morbidity, which can be expressed in many different organ systems." #PriovantTherapeutics #RareDisease #OrphanIndication #Uveitis #NIU #Dermatomyositis #JAK1 #TYK2 priovanttx.com Download the transcript here
Ben Zimmer, CEO of Priovant Therapeutics, focuses on developing therapies for rare autoimmune diseases specifically dermatomyositis, which affects the skin, muscles, and organs, and non-infectious uveitis, a severe ocular inflammatory condition. While these conditions are symptomatically different, mechanistically, they have features in common related to the underlying pathology of the diseases. The drug in development is an oral once-daily therapy that addresses the inflammatory conditions and cytokines driving the pathology. Ben explains, "During COVID, there was a lot of talk about the cytokine storm and these are molecules involved in immune cell signaling. So, they're basically ways that different types of immune cells signal to each other to do different things. There's a large variety of different cytokines and some autoimmune diseases. There are only maybe one or two cytokines or a small number that are driving the pathology of the disease." "Both dermatomyositis and non-infectious uveitis are highly inflammatory conditions with a lot of different pathogenic cytokines, a lot of different inflammatory axes involved. And so, one of the neat things about our drug, brepocitinib, is that it works on a set category of enzymes called JAKs, and then there are four different types of JAKs, JAK1, JAK2, JAK3, and you might guess JAK4, but it's actually called TYK2. And our drug inhibits TYK2 and JAK1. And by doing that, it suppresses the signaling of a large number of different cytokines." "Uveitis and dermatomyositis have a number of overlapping pathogenic cytokines involved, as well as some different cytokines, but they are both suppressed through the inhibition of TYK2 and JAK1, which our drug does. So, our thesis is to find these highly inflammatory indications, highly inflammatory diseases with high morbidity, which can be expressed in many different organ systems." #PriovantTherapeutics #RareDisease #OrphanIndication #Uveitis #NIU #Dermatomyositis #JAK1 #TYK2 priovanttx.com Listen to the podcast here
Jak's House Presented by Freejak (Episode 77) International DJ and award winning Producer Freejak brings 1 hour of the hottest new music from the finest Electronic producers and DJ's from around the world. This episode Freejak mixes up the hottest new electronic music, Including tracks from Cloonee, Yeah Yeah Yeahs, Maur, Chaney, Odd Mob, Sony Fodera, Dave Winnel and many more. FOLLOW FREEJAK ON SOCIALS. INSTAGRAM - SPOTIFY - FACEBOOK - WEB - SOUNDCLOUD -
Vanamehed viinavabriku kõrvalt püüavad sedapuhku lahata suuri dilemmasid, millele kestlikult kahanevatest paberlehtedest selget vastust ei leia: kas valmistuda sõjaks või lebada rahus? Kas osta pidulik pikk kleit või püsida kodus? Kas panna munakoored olmeprügisse või komposti? Ja mida sellest kõigest arvavad Liis Lemsalu, Pealtnägija ja rahvusringhäälingu turundusosakond?
Linnea Wikblad minns Diskoteksbranden i Göteborg och Matthew Perry som gick ur tiden. My Rohwedder ger oss ett Inrikespolitiskt svep. P3 Nyheters Babs Drougge om att en flygplats i delrepubliken Dagestans blev stormad i jakt på judar. Babs berättar även om om att flera regioner planerar att höja patientavgiften till akuten. David Druid reflektera då kring att män vägrar att söka vård. Årets kock Desirée Jaks om att göra soppa på en spik och vi får smaka på mumsig mat! Lyssna på alla avsnitt i Sveriges Radio Play. Programledare: David Druid, Linnea Wikblad
Desirée Jaks är en gastronomisk stjärna vars matlagning gjorde att hon med god marginal vann tävlingen Årets kock 2023. Vi får veta allt om hennes vinnarrätter och David Druid och Linnea Wikblad får smaska i sig lite lyxmat. Desirée berättar om hur hennes polska bakgrund påverkar hennes matlagning och hur det hjälpte henne i en deltävling. Lyssna på alla avsnitt i Sveriges Radio Play. Programledare: David Druid, Linnea Wikblad
KCBS Radio's Foodie Chap Liam Mayclem speaks with Jaks' Authentic Indian & Modern Vibe Chef Singh & owner Michael Agnel.
@DiscoverAg Instagram: 4.5k TikTok: 18.3k YouTube: 356 @nataliekovarik Instagram: 116kTikTok: 21.1k Twitter 2.3k. @taravanderdussenInstagram: 48.3k TikTok: 5.6k Catch UpWhere are they from, what do they farm, how did they get into farmingHow's the family - do they farm with family?Tara Vander Dussen & Natalie KovarikPodcast Discover Ag - Motto: “Agriculture you can relate to”Give their professional farming opinions on the top trending topics in the ag and food space to help you better understand the food system and connect with the hands the feed us~80 episodes started in April 2022How did they start? What motivated them? Who is their support system? What misinformation were you hearing that encouraged you to share the truth about myths? What is the audience you are trying to reach? How do you respond to negative comments or perception towards agriculture online? Do you notice differences in perception towards women in agriculture or online? What advice would you give to women who dream of a career in agriculture? Tara Vander DussenNew Mexico Native: Born and Raised5th Generation Diary Farmer and Farm Wife - grew up and now on a dairy farmGirl Mom to TwoWhiskey Drinker and Fast Talker (Auctioneer fast????)Lover of all things Southwest including Green Chile, Turquoise and Beautiful SunsetsAn environmental scientists on dairy farm projectsWhat are some of your proudest projects? Most challenging? Natalie KovarikMom to 3 Boys (Tad, Jaks, Rue) – killer namesFrom Central Nebraska Kovarik cattle Co - cow calf operation w/ a growing registered herdWhat is Elevate Ag? Online course and community where farmers, ranchers and other producers can come together to access the tools and information they need to craft, share, and monetize their own personal Ag story while confidently advocating for the Agriculture industry What responses from producers are you hearing back? Is Elevate Ag making a difference? Who can access this online course? What are the next steps to getting involved? How has hosting the Discover Ag changed their life? Why do it? How would they start it over differently?If you were an animal, what do you think you would be?Right now, who inspires you?If you could make anything bigger on your body what would it be? Start, Bench, CutBreakfast, lunch, dinnerTequila, vodka, wineYouTube, TikTok, FacebookDenim, sweatpants, chinosRoad trip, flying, cruisingShopping, museums, bar hopping What's next for them?What can our listeners do to help?What can we do to help?Knowing what you know now, what advice would you give yourself or others at 18?
Latvijas hokeja izlasei vēsturiska uzvara pār Zviedriju pasaules čempionāta pusfinālā ar 3:1. Pirmo reizi komandas vēsturē sasniegts turnīra pusfināls. Cīņā par vietu finālā Latvijas izlase sestdien Tamperē tiksies ar Kanādu. Vārtus Latvijai guva debitants Dans Ločmelis, Miks Indrašis un Jānis Jaks, bet uzvarētāju sastāvā par labāko spēlētāju atzina Rihardu Bukartu. Šis Latvijas izlases modelis šķir citu pēc citas jaunas vēstures lappuses: pirmo reizi pasaules čempionātā pusfināls, pirmo reizi tiks finišēts augstāk par septīto vietu, pirmo reizi izcīnītas sešas uzvaras pēc kārtas, pirmo reizi Zviedrija uzvarēta pamatlaikā. Komanda ir kā vienots veselums, ar izcilu vārtsargu un ārkārtīgi pašaizliedzīgi spēlējošiem laukuma spēlētājiem. Zviedrijas izlase ir Latvijas hokejistiem biežākais pretinieks pasaules čempionātos, abām komandām iepriekš tiekoties 17 reizes. Nevienā no šīm cīņām Latvijai nebija izdevies tikt pie uzvaras pamatlaikā.
Sarah Jaks, Associate Director for the Full-Time MBA Program at Texas A&M University's Mays Business School, is set on staying authentic throughout every aspect of life, whether work, volunteer activities, or being with friends and family. Jaks dives into her journey into student affairs and how her authentic leadership style allows her to thrive in her role. Additionally, she shares what sets Mays Business School's Full-Time MBA Program apart and how students transform during their time in the program. Bio: Sarah Jaks serves as the Associate Director for the Full-Time MBA Program at Mays Business School. She oversees the development, administration, and implementation of programs and services to provide a supportive educational environment for students in the MBA Program. She came to Texas A&M for her Masters' degree in 2009 and has since earned her PhD from Texas A&M in 2020. Prior to joining Mays in 2017, Sarah worked for 8 years in the Department of Student Life.
Sala Peau AKA DJ Jaks is a West Auckland DJ and part of Kut Man Krew Music and Outkast Entertainment NZ. Follow Outkast Entertainment on Instagram here: https://bit.ly/3VSyZPy --- Send in a voice message: https://anchor.fm/backofthe135/message
NATO valikud taas-pingestunud olukorras. Kas saklased tõesti kardavad ja valmistuvad suureks sõjaks? USA kui lääne turvalisuse garant - kas igavesti? Saadet juhib Neeme Raud.
During “The Great Debate” at ACR Convergence 2020, the question: “Should JAK inhibitors be started before TNF inhibitors in people with rheumatoid arthritis who failed methotrexate?” was asked. However, in 2021, results from the oral surveillance trial showed an increased risk of major adverse cardiovascular events in cancers among patients with rheumatoid arthritis taking tofacitinib as compared to those on TNF inhibitors. These findings led to the FDA updating their black box warning on JAK inhibitors. Today, we've invited one of the speakers on the great debate, Dr. Vibeke Strand, to speak on her position on JAK inhibitors given these new results and shed some more light on the subject.
Drs. George Martin and Ted Rosen talk candidly about why JAK inhibitors are important in the treatment of atopic dermatitis (AD), when dermatologists should consider using them, and how to safely mitigate risks and side effects while effectively treating AD patients with these powerful, “revolutionary” medications. 0:50 – The role of JAKs in AD 4:50 – JAK nuances 9:13 – The ORAL study and expanded black box warning 15:07 – Newer JAKS and Black Box inheritance 17:00 – The new molecules 18:00 – How to present biologics vs JAKs (age + delivery) 21:10 – Women of childbearing years 27:00 – Legacy black box on mace events, PEs, and DVTs – who's at risk? 30:44 – Cancer and risk 32:10 – Patients at risk for serious infections 35:27 – JAKs and vaccinations 38:47 – Dosing adjustments 46:20 – Final thoughts on biologics and JAKs
In this week's episode, Rebecca Jones is joined by Jaks Cunningham, founder of the Anderson Group. With over 16 years of business development experience, Cunningham recounts to us how her experiences have led her to where she is today. A self described adventurer, Cunningham remembers staking her claim on living on the West Coast when she was just a young girl with a love for Disneyland. Her experiences with dual citizenship have allowed her unique perspectives and has given her the grit to appreciate differences. One of Cunningham's biggest life lessons has been to not let other people's irrational fears hold you back. A natural conduit for connection, Cunningham has always had a knack for networking. While she recognizes that success may look different to everyone, her success is found through connecting people and letting the magic unravel on its own.When asked to give advice to young women following in her footsteps, Cunningham encourages girls to be gentle with the power you acquire. It's natural to be afraid of change, but ask yourself if it is fear or excitement. The most powerful tool a woman can have is to truly know and accept all aspects of herself.Thank you for listening and joining the SheEO Lead-In community!
Frohes Neues Jahr Ihr Lieben! Der Schornsteinfeger, der Fliegenpilz und das Glückschweinchen der Zauberkunst starten mit einer besonderen Folge ins neue Jahr. Andreas berichtet vom Sammlertreffen in Hamburg und seine Passion zu Stanley Jaks. David Copperfield lässt die Welt theoretisch in sein Museum und die drei Glückritter reiten auf historischen Pfaden Richtung Zukunft durch die Nacht. Alle Infos wie immer in den Show Notes.
This week we discuss a new lawsuit filed against notorious puppy mill broker, JAKS Puppies, and their associates, alleging a deliberate and coordinated effort by them to establish a sham rescue scheme in order to circumvent humane pet store laws. Learn about the different ways in which our research helps to provide the basis for this lawsuit and others, in order to try to hold puppy mill dealers accountable. Listen as we discuss the small world of puppy mill dealers and their interconnected networks. To learn more about this puppy mill broker, go here: https://bailingoutbenji.com/buyer-beware-jaks-puppies/Support the show (https://bailingoutbenji.com/support-us/)
Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.
In this week's episode, we'll learn about a new approach for targeting Janus kinases in CRLF2-rearranged ALL, discuss risk stratification for myeloid leukemia in children with Down syndrome and learn more about how sialic acid alterations on megakaryocyte antigens regulate immune cells and platelet production.
Prof Iain McInnes reviews two papers this month, and discusses the increased risk of HZ infection with upadacitinib, as well as the role of the JAK-STAT pathway in SpA pathenogenesis. Keep-up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.
In this episode editors Michael Flanagan and Simon King the FDA's new safety labelling for JAK inhibitors, impressive new data for Jardiance in heart failure and controversy around COVID-19 booster shots.
Hi Listeners, in this Lets Chat episode we will be chatting with Jak Tazzar of Semaphore. Jak is a Yoga/Meditation teacher, Chair yoga teacher, Divine Healer, Chakradance Facilitator and Workshop facilitator. Join us here in this episode to hear of Jaks journey from Scotland to India to Australia. AND Jak offers a BONUS and WONDERFUL meditation with Over-toning at the end of the episode. WOW, it will blow your Soul. Join in now. Jak can be contacted via: website: https://www.jaktazzar.com/ instagram: https://www.instagram.com/p/CIDfiCKjFv0/ --- Send in a voice message: https://anchor.fm/asharnaye/message
Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.
Roy Fleischmann, MD, discusses the recent Pfizer press release touching upon the safety of JAK inhibitors. He explains the recent scrutiny of JAKs, the concerns some rheumatologists have in regard to JAK inhibitors, and his personal opinions on prescribing JAK inhibiting drugs to his patients.
The Positive Effect - A retail leaders guide to changing the world
I will be chatting with Tim Dumas, Chief Operating Officer at JAKS, an independent retailer in Vancouver, on this week's live show. I met Tim as part of the John C. Maxwell Coaching team, and his retail career has been an interesting journey. As a leadership coach, his insights are always helpful, along with his career in leadership roles. I can't wait to learn about Tim's career and the lessons learned. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/april477/support
Logan and Lindsey Jaks, the owners of Wild Honey Tent Co, discuss their adventures in business ownership. --- Support this podcast: https://anchor.fm/alabamaentrepreneur/support
Lindsey Jaks, owner of Wild Honey Tent Co, discusses her customer service experience with a small business. --- Support this podcast: https://anchor.fm/alabamaentrepreneur/support
Nossos convidados contam como e porque decidiram voltar à Alemanha de forma definitiva após anos no Brasil e de ter trabalhado algumas temporadas em sorveterias alemãs. Episódio especial com padrinhos do podcast: Jaks e Suelen contam sua história em detalhes, falando sobre as experiências vividas na Alemanha quando trabalhavam em sorveterias. Também relataram a vontade [...] O post #61 Jaks e Suelen: Da sorveteria para a engenharia apareceu primeiro em Alemanha Cast.
Join Real Estate Experts Carrie Bobb, Melanie Haynes, and Jaks Cunningham on the All-In Podcast with Nate Peo Live. We will be discussing who these three are leveraging social media and branding to disrupt the way business gets done in commercial real estate. Connect with Carrie www.carriebobbandco.com https://hellojenny.com/ www.instagram.com/carriebobbandco/ Connect with Jaks https://www.linkedin.com/in/jaksanderson/ Connect with Melanie www.instagram.com/theindustrialchick/ Connect with Nate www.natepeo.com
You thought is never happen. You thought he was dead. We'll think again. Jaks back, and this time he's brought friends...but he forgot his computer skills. Enjoy!
© 2020-2026 Ivy Podcast Discovery LLC
